diphenhydramine/lorazepam/zolpidem (SM-1) / Eusol Biotech - LARVOL DELTA

An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Sequential Medicine Ltd | N=220 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • CNS Disorders • Insomnia • Sleep Disorder

An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia (clinicaltrials.gov) - P3 | N=220 | Not yet recruiting | Sponsor: Sequential Medicine Ltd | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • CNS Disorders • Insomnia • Sleep Disorder

An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia (clinicaltrials.gov) - P3; N=220; Not yet recruiting; Sponsor: Sequential Medicine Ltd; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Dec 2022

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Insomnia • Sleep Disorder

[VIRTUAL] Impact of sleep aid reduction strategies across a multi-hospital health system (ASHP 2020) - "The electronic medical record system will identify patients prescribed temazepam, alprazolam, lorazepam, zolpidem, diphenhydramine, trazodone, or doxepin (low dose) for insomnia during their admission at South Florida Baptist Hospital between April 2019 and October 2020...This data will be reviewed by clinical pharmacy personnel and health system leadership to determine whether medication-induced fall rates have decreased since initial evaluation one year ago. Results from the analysis will provide future direction to improving the utilization of sleep aid medications for our health system."

Clinical • Anesthesia • CNS Disorders • Insomnia • Sleep Disorder

Yaxiang Biomedicine: The company receives the manuscript of the research report on the small clinical trial of the sleep aid SM-1 in the United States [Google translation] (MoneyDJ) - "Yaxiang Biomedicine Announces a Small Clinical Trial Report on the Company's Sleep Aid SM -1...The company received a draft of the research report today (11/27), describing the research results obtained....The name of the trial plan: a randomized, double-blind, single-dose, two-way crossover design clinical trial...The sleep aid effect of SM-1...on patients with transient insomnia."

Clinical data • CNS Disorders • Insomnia • Sleep Disorder

Visible, Near-Infrared, and Dual-Range Luminescence Spanning the 4f Series Sensitized by a Gallium(III)/Lanthanide(III) Metallacrown Structure. (PubMed, J Phys Chem A) - "In the case of Sm-1, the values of Q in CHOH and CDOD solutions are exceptionally high, that is, 10.1(5) and 83(1) %. Values obtained for Yb-1, that is, 0.78(4) % in CHOH and 8.4(1)% in CDOD, are among the highest ones reported today for Yb complexes formed with nondeuterated and nonhalogenated ligands."

Journal

Prescription Medications for the Treatment of Insomnia and Risk of Suicide Attempt: a Comparative Safety Study. (PubMed, J Gen Intern Med) - "Compared to zolpidem, hazard of suicide attempt was 61% higher with trazodone (< 200 mg). No significant differences in suicide attempt risk were identified between benzodiazepines or sedating antihistamines and zolpidem, respectively. These findings provide the first comparative effectiveness evidence against the use of trazodone for insomnia."

Clinical • Journal • CNS Disorders • Insomnia • Pain • Psychiatry • Sleep Disorder • Suicidal Ideation

Examining aerobic degradation of chloroethenes mixture in consortium composed of Comamonas testosteroni RF2 and Mycobacterium aurum L1. (PubMed, Chemosphere) - "In this study, three vinyl chloride (VC) degrading strains, Mycobacterium aurum L1, Pseudomonas putida PS, and Rhodococcus ruber Sm-1 were used to form consortia with the strain RF2 in terms to achieve the removal of VC along with above-mentioned chloroethenes...The consortium composed of C. testosteroni RF2 and M. aurum L1 showed to be the most efficient towards the removal of cDCE (6.01 mg L) in the binary mixture with VC (10 mg L) and was capable of efficiently removing chloroethenes in the mixture sample at the initial concentrations of 116 μg L for TCE, 662 μg L for cDCE, 42 μg L for tDCE, 16 μg L for 1,1DCE, and 7 mg L for VC with a removal efficiency of nearly 100% for all of the compounds. Although complete removal of VC took a significantly longer time than the removal of other chloroethenes, the consortium composed of C. testosteroni RF2 and M. aurum L1 displayed strong..."

Journal

An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia (clinicaltrials.gov) - P3; N=220; Not yet recruiting; Sponsor: Sequential Medicine Ltd; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Insomnia • Sleep Disorder